14 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Will Incyte (INCY) Gain on Rising Earnings Estimates? http://www.zacks.com/stock/news/604570/will-incyte-incy-gain-on-rising-earnings-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-604570 Nov 05, 2019 - Incyte (INCY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/631099/mercks-keytruda-wins-eu-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631099 Nov 21, 2019 - Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag http://www.zacks.com/stock/news/644810/incytes-nda-for-pemigatinib-gets-fdas-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-644810 Nov 28, 2019 - The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Has Incyte (INCY) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/686067/has-incyte-incy-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-686067 Dec 24, 2019 - Is (INCY) Outperforming Other Medical Stocks This Year?
A $20 Billion Sweet Spot in Biotech https://www.fool.com/investing/2019/12/28/a-20-billion-sweet-spot-in-biotech.aspx?source=iedfolrf0000001 Dec 28, 2019 - Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
INCY, LNDC among premarket losers https://seekingalpha.com/news/3529502-incy-lndc-among-premarket-losers?utm_source=feed_news_all&utm_medium=referral Jan 03, 2020 - Novan (NASDAQ:NOVN) -73% on failed SB206 study.DPW Holdings (NYSEMKT:DPW) -30% on doubts over FINRA approval of proposed acquisitions.Landec (NASDAQ:LNDC) -15% on Q2 earnings.Mereo BioPharma Group (NA
INCY: BMO Capital Markets reits Market Perform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20200103142954 Jan 03, 2020 - BMO Capital Markets issues rating change for INCY
Company News For Jan 6, 2020 http://www.zacks.com/stock/news/704772/company-news-for-jan-6-2020?cid=CS-ZC--corporate_summary-704772 Jan 06, 2020 - Companies In The News Are: CANF, LW, INCY, NOVN
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data http://www.zacks.com/stock/news/708127/biotech-stock-roundup-updates-from-incy-exel-apls-life-surge-on-positive-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-708127 Jan 08, 2020 - A low-key week for the biotech sector, with a few pipeline and regulatory updates.
4 Big Biotech Stocks Worth Considering Post Q3 Earnings http://www.zacks.com/stock/news/627538/4-big-biotech-stocks-worth-considering-post-q3-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-627538 Nov 19, 2019 - We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

Pages: 12

Page 1